Clinical Trial Update: XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer [NA]

View source ↗

Summary

A clinical trial update states that XH001 is being studied in combination with an immunocheckpoint inhibitor and chemotherapy for patients with resected pancrea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• XH001 (XH001)

Snippet

Sponsor: Wu Wenming | Conditions: Pancreatic Cancer | NA | Status: RECRUITING